How to know your Alzheimer’s risk

How to know your Alzheimer’s risk? Check the options below.
Except for 23andMe, every test requires a doctor’s prescription, but they are generally accessible through private clinics.
This list includes only assays with some form of regulatory clearance; it is not comprehensive (other companies may offer comparable tests).
Some of the options estimate long-term risk (about 10 years), and others measure current biological changes that increase your shorter-term risk (about 3-5 years).
Blood-based markers such as p-tau217 are moving fast. Recent reporting suggests they can spot Alzheimer’s biology years earlier, with accuracy figures around 90% in some settings [31, 32]. That is why catalogues like this matter: knowing which tool answers which question is half the battle.
DNA tests
23andMe APOE ε4 Genotyping
- Company: 23andMe
- Accuracy: 99% in detecting the mutation [1]
- Status: FDA-authorized [2]
- Country: US, UK, Denmark, Finland, Ireland, Netherlands and Sweden [3]
- Price: $199 [4]
Invitae Hereditary Alzheimer’s Disease Panel (APP, PSEN1, PSEN2)
- Company: Invitae (Labcorp)
- Accuracy: 99% in detecting the mutations [5]
- Status: CLIA-certified, not FDA-cleared [5]
- Country: US, and case-by-case in EU [5]
- Price: from $299 [6]
Blood tests
Lumipulse G p-tau217 / β-amyloid 1-42
- Company: Fujirebio
- Accuracy: 94% when “indeterminate” results are excluded; 75% when counted as incorrect [7]
- Status: FDA-cleared [8]
- Country: US [8]
- Price: $500 - $1,000 [9]
PrecivityAD2 p-tau217 + Aβ42/40
- Company: C2N Diagnostics
- Accuracy: 88% [10]
- Status: CLIA LDT, not FDA-cleared [11] and MHRA certified [12]. Previous version (PrecivityAD) CE marked [13]
- Country: US [11] and UK [12]. Previous version (PrecivityAD) in EU [13]
- Price: $1,450 [14]
LucentAD p-tau217
- Company: Quanterix
- Accuracy: 93% [15]
- Status: CLIA LDT, not FDA-cleared [16][17]
- Country: US [16]
- Price: $300 [14]
CSF, PET and MRI
Lumipulse G β-amyloid Ratio (CSF)
- Company: Fujirebio
- Accuracy: 90% [18]
- Status: FDA approved [18] and CE marking [19]
- Country: US [20] and EU [19]
- Price: $800 - $1,500 [21]
PET: β-amyloid neuritic plaque density
- Company: Eli Lilly (Amyvid / Avid), Life Molecular Imaging (Neuraceq), GE HealthCare (Vizamyl)
- Accuracy: 95% [22]
- Status: FDA and EMA approved [22]
- Country: US [23] and EU [22]
- Price: about $5,000 [24]
PET: aggregated tau neurofibrillary tangles
- Company: Eli Lilly (Tauvid)
- Accuracy: 78%-92% [25]
- Status: FDA and EMA approved [26]
- Country: US and EU [26]
- Price: about $5,000 [24]
MRI: NeuroQuant volumetric brain and ARIA
- Company: Cortechs.ai
- Accuracy: 84% [27]
- Status: FDA cleared [28] and CE marked [29]
- Availability: US [28], UK and EU [29]
- Price: $500 - $600 [30]
If you want the prevention levers that matter once you know your risk, see People do want to know their Alzheimer’s risk.
References
- 23andMe Genetic Health Risk Report package insert
- FDA, Direct-to-consumer tests
- 23andMe shipping countries
- 23andMe DNA Health + Ancestry
- Invitae Hereditary Alzheimer’s Disease Panel
- Invitae billing
- FDA K242706 decision summary
- FDA clears first blood test used in diagnosing Alzheimer’s disease
- What to know about the new blood test for Alzheimer’s
- PrecivityAD2 accuracy evidence
- C2N PrecivityAD2 clinical-care release
- C2N PrecivityAD2 MHRA certification
- PrecivityAD CE marking coverage
- Being Patient on Alzheimer’s blood-test pricing
- LucentAD accuracy poster update
- Quanterix p-tau217 blood biomarker launch
- LucentAD Complete
- FDA DEN200072 review
- Fujirebio Lumipulse G beta-amyloid 1-40
- FDA permits marketing of CSF Alzheimer’s test
- AAFP diagnostic tests for Alzheimer disease
- EMA Amyvid assessment report
- FDA Amyvid clinical pharmacology review
- Radiology Today on PET pricing context
- Lilly Tauvid accuracy information
- Flortaucipir legal status overview
- NeuroQuant accuracy preprint
- FDA clears NeuroQuant 5 software
- NeuroQuant CE marking
- MD Save NeuroQuant pricing example
- CNN on Alzheimer’s blood biomarkers
- Eric Topol on the breakthrough blood test for Alzheimer’s